Acute GVHD occurs in nearly 50% of patients receiving hematopoietic cell transplantation (HCT), and is the major driver of mortality. However, progress in the development of new acute GVHD therapeutics has been slow, in part due to heterogeneity in acute GVHD data collection and interpretation among centers. Herein, we first describe the methods used by the Mount Sinai Acute GVHD International Consortium (MAGIC) to standardize acute GVHD data collection and curation. We then review the utility of serum biomarkers, specifically the MAGIC Algorithm Probability (MAP) that combines two GI biomarkers (ST2 and REG3α) that has been shown to be more accurate than changes in clinical symptom severity after GVHD treatment. We then present preliminary data on the feasibility of a surrogate clinical trial endpoint that combines clinical response and MAP two weeks after treatment. This novel endpoint is an earlier and potentially better predictor of non-relapse mortality than the current gold standard of clinical response four weeks after treatment.

Original languageEnglish
Article number101400
JournalBest Practice and Research: Clinical Haematology
Issue number4
StatePublished - Dec 2022


  • Acute graft versus host disease
  • Biomarkers
  • Clinical trial endpoint
  • Composite endpoint
  • MAGIC Algorithm Probability
  • Mount Sinai Acute GVHD International Consortium
  • Surrogate endpoint


Dive into the research topics of 'Acute GVHD: New approaches to clinical trial monitoring'. Together they form a unique fingerprint.

Cite this